VISCHER advised the prominent US hedge fund Elliott on certain Swiss law matters in its proxy solicitation for a number of proposed changes to the board and the corporate governance of Actelion Ltd, one of the largest Swiss pharmaceutical corporations with SMI listing. The campaign was launched in 2011 and although not ultimately successful, received widespread public attention within Switzerland and in the international press. It was one of the first US-style proxy fights by a minority shareholder ever seen in the Swiss market. The team was led by partner Dr. Markus Guggenbühl and included Dr. Matthias Glatthaar and other associates.